AI Article Synopsis
- - France has a high rate of head and neck cancers, yet the role of high-risk human papilloma virus (HR-HPV) in these cancers is not well understood
- - A study in 15 hospitals found that 37.7% of oropharyngeal cancers were linked to HR-HPV, with better outcomes for patients who had HPV-driven cancers compared to those who did not
- - The findings highlight that over a third of certain throat cancers in France are driven by HPV, emphasizing the need for further research on the progression of these cancers.
Article Abstract
Background: France has one of the highest incidence of head and neck cancers in Europe. Despite this, the epidemiological impact of high-risk human papilloma virus (HR-HPV) remains poorly investigated.
Methods: We prospective assessed the proportion of oropharyngeal cancers due to HR-HPV in 15 hospitals throughout France. HPV-status was determined by p16-immunohistochemistry, and by detection of HPV-DNA using in situ hybridization. Cancers were classified as HPV-driven if both p16-immunohistochemistry and HPV-DNA assays were positive. Demographical and clinical features were recorded.
Results: 291 patients with palatine-tonsil or tongue-base cancers were recruited from March-2011 to July-2012. Of these, 43.1% of samples were p16-positive and 37.7% were positive for both p16 and HPV-DNA. Prognosis was significantly better in patients with HPV-driven cancers, with smoking negatively impacting patients' oncological outcomes.
Conclusion: In France, more than a third of tonsillar and tongue base cancers are HPV-driven. More research concerning the evolution of HPV-driven cancers over time is needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canep.2019.05.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!